Literature DB >> 3581428

Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Fischer rats.

E F Lhoste, B D Roebuck, T Brinck-Johnsen, D S Longnecker.   

Abstract

Previous reports have shown that pancreatic cancer was induced preferentially in male versus female azaserine-treated rats. This study was designed to determine the importance of estrogen and testosterone in this phenomenon. Fischer (F344) rats received a single injection of azaserine (30 mg/kg) at 21 days of age. At 28 days of age, they were weaned and divided into 12 groups of 9-10 rats as shown below. Surgery (castration or sham operation) was performed at 4 weeks of age. All drugs (estradiol, the antiestrogen tamoxifen, testosterone propionate and/or the antiandrogen flutamide) were administered, starting at weaning, in 3-week timed-release pellets until autopsy. Rats were killed 4 months after the administration of azaserine. The pancreas was weighed and prepared for quantitative histologic analysis of atypical acinar cell nodules (AACNs) which are putative preneoplastic lesions. Both number and size of AACNs were analyzed. In intact female rats, AACN burden was smaller than in intact males (P less than 0.05). Ovariectomy increased the AACN burden (P less than 0.05), while estradiol or tamoxifen treatments to ovariectomized females resorted the burden to control levels (P less than 0.05). Testosterone with tamoxifen treatment to ovariectomized females led to a significant increase in AACN burden over control values. In intact male rats, orchiectomy decreased the AACN burden (P less than 0.05). In orchiectomized rats, testosterone treatment slightly increased the AACN burden, flutamide treatment alone increased this parameter (P less than 0.05) but flutamide with estradiol decreased the AACN burden (P less than 0.01). These data strongly support the hypothesis that sex steroids play a major role in the higher incidence of pancreatic cancer in male versus female rats.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3581428     DOI: 10.1093/carcin/8.5.699

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  10 in total

Review 1.  Chemoprevention for pancreatic cancer.

Authors:  Robert A Wolff
Journal:  Int J Gastrointest Cancer       Date:  2003

2.  Characteristics of pancreatic carcinoma in the elderly.

Authors:  T Kamisawa; T Yuyang; N Egawa; J Ishiwata; K Tsuruta; A Okamoto; M Koike
Journal:  Int J Pancreatol       Date:  1998-08

3.  Effects of sex steroid hormones on pancreatic cancer in the rat.

Authors:  D S Longnecker; C Sumi
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

Review 4.  Hormonal therapy of pancreatic carcinoma. Rationale and perspectives.

Authors:  D Perilli; C Mansi; V Savarino; G Celle
Journal:  Int J Pancreatol       Date:  1993-06

5.  Effects of orchiectomy, alone or in combination with testosterone, and cyproterone acetate on exocrine pancreatic carcinogenesis in rats and hamsters.

Authors:  M Meijers; C J Visser; J G Klijn; S W Lamberts; A van Garderen-Hoetmer; F H de Jong; J A Foekens; R A Woutersen
Journal:  Int J Pancreatol       Date:  1992-04

6.  Serum levels of sex hormones and corticosterone throughout 4- and 5-day estrous cycles in Fischer 344 rats and their simulation in ovariectomized females.

Authors:  S Haim; G Shakhar; E Rossene; A N Taylor; S Ben-Eliyahu
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

Review 7.  Androgen influence on exocrine pancreatic cancer.

Authors:  A Andrén-Sandberg
Journal:  Int J Pancreatol       Date:  1989-05

8.  Exocrine pancreatic carcinogenesis and autotaxin expression.

Authors:  Sandeep Kadekar; Ilona Silins; Anna Korhonen; Kristian Dreij; Lauy Al-Anati; Johan Högberg; Ulla Stenius
Journal:  PLoS One       Date:  2012-08-29       Impact factor: 3.240

Review 9.  AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.

Authors:  Michael T Schweizer; Evan Y Yu
Journal:  Cancers (Basel)       Date:  2017-01-11       Impact factor: 6.639

Review 10.  Androgen-Induced Immunosuppression.

Authors:  Melanie R Gubbels Bupp; Trine N Jorgensen
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.